Cirsium bracteosum
Cirsium bracteosum · Accepted scientific name
Scientific literature: Very Sparse (1 studies) · ★☆☆☆☆
Cirsium bracteosum is a botanical species that has garnered significant scientific interest due to its unique biological properties. Research into this plant has specifically highlighted its potential antineoplastic activities, suggesting a role in cancer research. Scientists frequently utilize various preparation methods to isolate its bioactive components for study. Among these methods, the production of methanolic extracts has proven particularly effective for concentrating its medicinal compounds. Understanding these chemical profiles is essential for exploring the plant's therapeutic applications in modern medicine.
- Synonyms
- Lophiolepis Bracteosa · Cirsium Campylolepis
- Common names
- Not available
- Family
- Asteraceae
- Distribution
- Southern America
- Plant Parts
- Not available
Classification
Synonyms
Cirsium bracteosum is a botanical species that is frequently identified by several different scientific names. Within various taxonomic records, it is recognized by the synonym Cirsium campylolepis. Additionally, the plant is documented under the alternative designation Lophiolepis bracteosa. These overlapping names often reflect the evolving nature of botanical classification and historical research. Understanding these synonyms is essential for researchers seeking to maintain accurate records of the species.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Cirsium bracteosum is a distinctive botanical specimen that belongs to the kingdom Plantae. Within this vast kingdom, it is specifically classified under the class Equisetopsida. The plant is a member of the order Asterales, showcasing its evolutionary connections to other flowering species. More narrowly, it falls under the family Asteraceae, a group known for its diverse floral structures. Ultimately, this species is defined by its placement within the genus Cirsium.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Asterales |
| Family | Asteraceae |
| Genus | Cirsium |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Cirsium bracteosum is a plant species primarily distributed across the temperate regions of Asia. Its natural range encompasses the rugged landscapes of the Caucasus and the Transcaucasus. Furthermore, this species can be found throughout Western Asia, specifically within the territories of Iran and Iraq. The plant also maintains a significant presence in the diverse terrains of Türkiye. Together, these regions define the unique geographical footprint of this thistle.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Cirsium bracteosum is characterized by its distinct growth form as a herbaceous plant.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Cirsium bracteosum has demonstrated significant antineoplastic activity in recent studies investigating native Iranian medicinal plants. Research specifically highlighted its effectiveness against the K562 leukemia cell line, where it exhibited a potent inhibitory effect. The methanolic extract of this plant achieved an IC50 value of less than 20 microg/ml, marking it as one of the most active substances tested. While it successfully decreased tumor cell proliferation, further analysis showed it did not significantly alter the cell cycle profile or induce DNA fragmentation in certain lines. Ultimately, these findings underscore the potential of Cirsium bracteosum as a candidate for further anticancer drug development.
Compounds
Conditions
Cirsium bracteosum demonstrates significant antineoplastic activity, specifically showing high efficacy against the K562 leukemia cell line with an IC50 of less than 20 microg/ml. This plant extract serves as a potent agent in reducing the proliferation of these specific tumor cells. Beyond its anticancer properties, the plant also exerts an immunomodulatory effect on human lymphocytes. When lymphocytes are treated with Cirsium bracteosum, their proliferation is inhibited in a dose-dependent manner. These findings highlight the plant's dual capacity to treat leukemia cells and regulate lymphocyte growth.
Preparations
Cirsium bracteosum is prepared as an extract to investigate its various biological properties in medicinal studies. Specifically, this plant is prepared as methanolic extracts to evaluate its potential antineoplastic activity against human tumor cell lines. Research shows that these extracts can inhibit lymphocyte proliferation in a dose-dependent manner. Furthermore, the methanolic extracts of Cirsium bracteosum demonstrate significant activity against the K562 leukemia cell line. These preparations are central to understanding the plant's capacity to decrease the proliferation of specific cancer cells.